focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Dealing

14 Oct 2015 17:13

RNS Number : 3070C
PuriCore Plc
14 October 2015
 



 

 

PuriCore plc

("PuriCore" or the "Company")

 

Director Dealing

 

 

14 October 2015 - PuriCore plc (AIM: PURI), an international company focused on applying its proprietary hypochlorous acid platform technology to unmet needs in human health, announces that, on 14 October 2015, the Director named below notified the Company that he had purchased ordinary shares of 10p each in the share capital of the Company ("Shares").

 

 

Name

Date purchased

Number of Shares purchased

Purchase price of Shares

Shareholding following the purchase

% of issued share capital

Daniel Hegglin Non-Executive Director

13 October 2015

500,000

18p

5,909,091

11.79%

 

-Ends-

 

Enquiries:

 

PuriCore plc

+44 (0) 20 3727 1000

 

Alex Martin, Chief Executive Officer

Marella Thorell, Chief Financial Officer and Chief Operating Officer

 

FTI Consulting

+44 (0) 20 3727 1000

 

Simon Conway / Mo Noonan / Victoria Foster Mitchell

 

 

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

 

Aubrey Powell / Jen Boorer / Thomas Smale

 

 

About PuriCore

PuriCore is an international company, focused on developing and commercialising products based on its proprietary hypochlorous acid platform technology, to address significant unmet needs in human health. PuriCore's products are currently used in two broad market segments: Supermarket Retail and Health Sciences. PuriCore's products do not cause harm to human or animal life or to the environment. The Group is headquartered in Malvern, Pennsylvania.

 

In the Supermarket Retail segment, PuriCore's products are used by customers to enhance quality and freshness of produce and floral products. Product offerings include the Sterilox® Fresh Systems (capital equipment) that are installed at customer locations and allow for generation of the solution as needed at the store. ProduceFresh® is the Company's concentrate bottled version of the solution for produce application. Customers use FloraFresh®, also sold as a concentrate in bottled form, to improve the freshness of cut flowers. ProduceFresh and FloraFresh are diluted for use by customers through the Company's concentrate delivery systems.

 

In Health Sciences, PuriCore offers a range of products to manage a variety of skin and wound conditions under a medical device registration.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSGGGPGUUPAGQC
Date   Source Headline
4th Jun 20144:46 pmRNSPublication of Circular
4th Jun 20147:00 amRNSSale of Endoscopy Business
14th May 20147:00 amRNSInterim Management Statement
24th Apr 20147:00 amRNSFinal Results
10th Apr 20147:00 amRNSNotice of Results
19th Feb 201411:22 amRNSBlocklisting Interim Review
18th Feb 20147:00 amRNSTrading Statement
13th Feb 20147:00 amRNSMiddle East Wound Care Marketing Agreement
7th Nov 20137:00 amRNSRe Agreement
6th Nov 20138:50 amRNSHolding(s) in Company
4th Nov 201310:03 amRNSHolding(s) in Company
1st Nov 20137:00 amRNSDirector/PDMR Shareholding
28th Oct 20137:00 amRNSInterim Management Statement
22nd Oct 20137:00 amRNSLaunches New Animal Health Wound Product NovaZo
15th Oct 20137:00 amRNSDirector Details
11th Oct 20137:00 amRNSReached agreement with Misonix
27th Sep 20137:00 amRNSValue Creation Plan Update
6th Sep 20131:58 pmRNSDirector Dealing
16th Aug 20133:24 pmRNSDirector Dealing
12th Aug 20131:59 pmRNSShare Option Grant
8th Aug 20137:00 amRNSHalf Yearly Report
2nd Aug 20137:00 amRNSBlocklisting Interim Review
17th Jul 20137:00 amRNSNotice of Results
28th Jun 20137:00 amRNSTotal Voting Rights
26th Jun 201311:19 amRNSResult of AGM
20th Jun 20137:00 amRNSPuriCore signs $13.5 million US deal
19th Jun 20131:16 pmRNSAGM Update
11th Jun 20133:08 pmRNSHolding(s) in Company
11th Jun 20133:06 pmRNSHolding(s) in Company
5th Jun 20131:13 pmRNSHolding(s) in Company - Replacement
5th Jun 20131:10 pmRNSHolding(s) in Company - Replacement
4th Jun 20133:04 pmRNSHolding(s) in Company
4th Jun 20133:01 pmRNSHolding(s) in Company
17th May 20137:46 amRNSInterim Management Statement
14th May 20137:00 amRNSBoard Changes
2nd May 20137:00 amRNSShare Option Grant
1st May 20137:00 amRNSTotal Voting Rights
30th Apr 20137:00 amRNSFinal Results
17th Apr 20131:57 pmRNSNotice of Results
8th Apr 20137:00 amRNSPuriCore Signs Major US Deal
3rd Apr 20137:00 amRNSPuriCore Signs Vashe Marketing Agreement
7th Mar 20137:00 amRNSTrading Update
6th Mar 20137:00 amRNSPuriCore Partners with Onset Dermatologics
5th Mar 20137:00 amRNSBoard and Organisational Changes
15th Feb 20135:20 pmRNSBlocklisting Interim Review
14th Feb 20137:00 amRNSFDA 510(k) Clearance
12th Feb 20136:01 pmRNSShare Option Grant and Blocklisting Update
7th Feb 20135:39 pmRNSApplication for Blocklisting
1st Feb 20134:40 pmRNSSecond Price Monitoring Extn
1st Feb 20134:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.